Since 31 December 2019, after the World Health Organization has been reported for the first cases of coronavirus in Wuhan City, Hubei Province, China, the world has never been the same. As the COVID-19 vaccines aren’t as easy to access in many countries, people keep suffering and facing an enemy constantly changing, highly contagious and unable to stop at any time soon.
Though they’re developing for the new variants of this life-taking devastating disease, the scientists have not given up in attempts to find a different treatment to finally crush SARS-Cov-2 once and for all. And if a month ago that seemed completely impossible, for a couple of weeks one revolutionary discovery made us believe tables have turned on our request.
A Vancouver based biotech corporation SaNOtize Research & Development Corp. (SaNOtize) announced they have approval to sell their Nitric Oxide Releasing Solution (NORSTM) in Israel and New Zealand. What’s more amazing, their CEO Gilly Regev claimed the nasal spray to be more than 99,9 % effective in killing COVID-19, by preventing its way from the upper airways to the lungs.
As we know, nitric oxide is neither unknown, nor an inexperienced antimicrobial and an antiviral nanomolecular agent in a whole range of bacterial, viral and fungal diseases, including COVID-19. Its’ success with coronaviruses dates back to 2003 SARs-CoV-1 epidemia, goes through 2019 in several studies worldwide and ends up by completely curing 6 pregnant women hospitalized with severe or critical COVID-19 in MGH.
While now this seems to be one of the top stories circulating in the web, it appears NORS have made a long journey to be able to shine as a rising star in the pandemic outbreak, and move in from lab tests, studies and trials, in order to walk on the red carpet of approval.
It turns out SaNOtize has been looking for strategic and financial partners for its’ NORS project back in November 2018, but it reaches out popularity, after developing a partnership with its biggest Israeli venture investor OurCrowd in 22 November 2020. That’s when it’s effectiveness in fighting COVID-19 disease from the beginning is first advertised.
Everyone knows the virus is spreading, as it enters through the nasal passages. Characterized as a hand sanitizer for your nose, SaNOtize chief scientist Dr. Chris Miller and the CEO Gilly Regev explain in details how that simple spray can protect you in contact with a person, who’s sick of COVID-19 virus, even in close contact and overcrowded places, where prevention is almost unachievable.
It seems all you have to do after being exposed to a possibility to be infected, all you have to do is remove your mask, give a click in both of your nostrils, and put it again. I hardly ever believe there’s anything more easy in killing the coronavirus at allq and prevents it from multiplying across your body.
But until they came to discuss it on public, SaNOtize have already gained NORS approval of Health Canada for moving from enrolling its first patient into the chronic sinusitis to Phase II Trial in using it in potential COVID-19 treatment.
After building a partnership with the Institute for Antiviral Research at Utah State University, the company proved again its’ 99.9 % efficiency for only 5 minutes, in laboratory testing, and remembered nitric oxide as a 2-part nanomolecule, able to prevent a wide variety of viruses, bacteria and fungi.
As receiving a “No Objection Letter” from Health Canada to proceed to Phase IIb/III of the multinational clinical trial, SaNOtize have been aiming at a new goal: moving directly to Phase IV, which is approval for selling the product on the market worldwide.
In order to do that, trials in Quebec, BC, Montreal and UK have been initiated, focusing on volunteers of the highest risk groups, like front-line health workers and those in contact with positive-tested, as well as positive-tested in an early stage of infection.
Finally, the results in the UK Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, again confirmed NORS really has a potential in joining the global fight with COVID-19. In a randomized, placebo-controlled, double-blinded trial among 79 confirmed cases of COVID-19, mostly infected with the UK variant, it reduced the viral level with more than 95 % for a 24 hours period, reaching out more than 99 % for 48 hours.
However, the last thing, achieved so far, was manufacturing the amazing spray back home, in Israel, and earning New Zealand Medicines and Medical Devices Safety Authority permission to distribute and sell ASP.
MVS Pharma GmbH is an innovative pharmaceutical start-up company, which researches in the area of reducing viruses and bacteria with plant based aerosols. Their special formula ensures the purity and the stability of the used ingredients during storage.
Liliya Ganeva is an article writer, who explores all the actual, up-to-date COVID-19 information, and the possibilities for producing aerosols made out of plants against respiratory viruses and bacteria.